PURPOSE: We sought to test the applicability of a well-documented visual function assessment (VF-14) in corneal disease patients wait-listed for penetrating keratoplasty to determine if it would be a valuable addition to a priority scheme. METHODS: A systematic random sample of patients wait-listed for penetrating keratoplasty in British Columbia was selected and administered the VF-14. RESULTS: The mean VF-14 score was 67.2; it was correlated with best corrected vision. Immigrants had lower VF-14 scores and they considered fewer of the questions applicable to them. There was a correlation between the number of questions considered applicable and the VF-14 score. CONCLUSIONS: As currently constituted the VF-14 is probably not a useful tool in a multi-cultural population in North America. We propose revisions to the visual function assessment and suggest its inclusion in a priority scheme for penetrating keratoplasty that also includes pain and other clinical indices.
PURPOSE: We sought to test the applicability of a well-documented visual function assessment (VF-14) in corneal diseasepatients wait-listed for penetrating keratoplasty to determine if it would be a valuable addition to a priority scheme. METHODS: A systematic random sample of patients wait-listed for penetrating keratoplasty in British Columbia was selected and administered the VF-14. RESULTS: The mean VF-14 score was 67.2; it was correlated with best corrected vision. Immigrants had lower VF-14 scores and they considered fewer of the questions applicable to them. There was a correlation between the number of questions considered applicable and the VF-14 score. CONCLUSIONS: As currently constituted the VF-14 is probably not a useful tool in a multi-cultural population in North America. We propose revisions to the visual function assessment and suggest its inclusion in a priority scheme for penetrating keratoplasty that also includes pain and other clinical indices.
Authors: Patrick P R Saunders; Lyn M Sibley; John S F Richards; Simon P Holland; Debbie L Chow; Paul Courtright Journal: Br J Ophthalmol Date: 2002-01 Impact factor: 4.638
Authors: K van Dijk; S Lewallen; M Chirambo; J Gardiner; B Hoar; J Lindley; N K Wade; P Courtright Journal: Br J Ophthalmol Date: 1999-07 Impact factor: 4.638